Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis

Abstract Liver fibrosis represents the main risk factor not only for liver-related but also for overall mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) patients, being metabolic dysfunction-associated steatohepatitis (MASH) its more severe clinical form. We recently dev...

Description complète

Détails bibliographiques

Auteurs principaux:	Stephania C. Isaza, Carlos Ernesto Fernández-García, Diego Rojo, Paula Iruzubieta, Javier Ampuero, Rocío Aller, Raquel Vinuesa Campo, Laura Izquierdo-Sánchez, Esther Fuertes-Yebra, Patricia Marañón, Jesús M. Banales, Laura Pagés, Carolina Jiménez-González, Javier Rodríguez de Cía, Irene Olaizola, Judith Gómez-Camarero, Víctor Arroyo-Lopez, Manuel Romero-Gómez, Javier Crespo, Juan M. Pericàs, Carmelo García-Monzón, Águeda González-Rodríguez, on behalf of HEPAmet Registry
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-11-01
Collection:	Biomarker Research
Sujets:	Advanced liver fibrosis MASLD MASH BMP8A BFS Non-invasive diagnosis
Accès en ligne:	https://doi.org/10.1186/s40364-025-00862-3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!